Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Test Could Detect Risk of Viral Infection-Induced Cardiac Arrest

By LabMedica International staff writers
Posted on 07 Mar 2024

Myocarditis, an inflammation of the heart often caused by the body's immune response to a viral infection, can cause sudden cardiac death. More...

Alarmingly, myocarditis accounts for up to 42% of sudden cardiac deaths in young adults, with viral infection being the primary cause. Traditionally, clinical understanding has focused on how inflammation affects heart rate or rhythm. Now, a new understanding from the latest research suggests completely different directions to diagnose and treat viral infections affecting the heart

A new study led by scientists from the Fralin Biomedical Research Institute at Virginia Tech (Blacksburg, VA, USA) has discovered that the virus itself can create dangerous conditions in the heart even before inflammation begins. The study identified an acute phase where the virus first invades the heart, preceding the onset of inflammation due to the body’s immune response. This early infection stage sets the stage for arrhythmias before any tissue inflammation. The research specifically examined adenovirus, often involved in cardiac infections and myocarditis, using Mouse Adenovirus Type-3 to mimic the human infection process. They discovered that at the onset of infection, the virus interferes with essential elements of the heart’s communication and electrical systems, leading to potential disruptions even before symptoms appear. The infection affects the heart's gap junctions, the communication channels between heart cells, and ion channels, the regulatory gates in cell membranes essential for maintaining ion balance crucial for normal heart electrical activity and beating.

When these communication systems and regulators are disturbed by the adenoviral infection, the heart may develop irregular electrical activity patterns known as arrhythmias, impacting its ability to beat and pump blood effectively. This can result in sudden cardiac issues, particularly in individuals with active infections. With the focus now shifting to molecular-level interventions targeting heart arrhythmias caused by viral infections, the researchers now plan to explore methods to detect blood biomarkers indicative of these severe conditions. The aim is to identify high-risk individuals through a simple blood test at the doctor's office, potentially transforming the approach to managing viral cardiac infections.

“Individuals who have acute infections can look normal by MRI and echocardiography, but when we delved into the molecular level, we saw that something very dangerous could occur,” said James Smyth, associate professor at the Fralin Biomedical Research Institute, who led the research. “In terms of diagnostics, we can now work with our colleagues here to start looking ways to analyze blood for a biomarker of the more serious problem. People get cardiac infections all the time and they recover. But can we identify what's different about individuals that are at a higher risk to have the arrhythmia, possibly through a simple blood test in the doctor's office.”

Related Links:
Virginia Tech


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.